Multicenter Study Of CPX-1 (Irinotecan HCl: Floxuridine) Liposome Injection In Patients With Advanced Colorectal Cancer
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether CPX-1 is effective in patients with
advanced colorectal cancer who have already received chemotherapy that included the drug
oxaliplatin or irinotecan. All patients will receive CPX-1 at a dose of 210 units/m2 over 90
minutes every two weeks.